Sirohi Deepika, Smith Steven C, Ohe Chisato, Colombo Piergiuseppe, Divatia Mukul, Dragoescu Ema, Rao Priya, Hirsch Michelle S, Chen Ying-Bei, Mehra Rohit, Amin Mahul B
Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Departments of Pathology and Urology, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA.
Hum Pathol. 2017 Sep;67:134-145. doi: 10.1016/j.humpath.2017.07.006. Epub 2017 Jul 15.
Renal medullary carcinoma (RMC) is a highly aggressive renal cell carcinoma arising in the collecting system and requiring careful correlation with status of sickle cell trait. A panel of international experts has recently proposed provisional diagnostic terminology, renal cell carcinoma, unclassified, with medullary phenotype, based on encountering an extraordinarily rare tumor with RMC morphology and immunophenotype in an individual proven not to have a hemoglobinopathy. Herein, we extend this observation to a cohort of 5 such tumors, morphologically similar to RMC, lacking SMARCB1 expression by immunohistochemistry, but each without evidence of a hemoglobinopathy. The tumors arose in 4 men and 1 woman with a mean age of 44 years, occurring in 3 left and 2 right kidneys. Clinically, aggression was apparent with involvement of perinephric adipose tissue in all 5 cases, nodal metastasis in 4 of 5 cases, and death of disease in 4 of 5 cases within 3-27 months. Histologic sections showed poorly differentiated adenocarcinoma, often with solid and nested growth patterns, as well as infiltrative glandular, tubulopapillary, cribriform, or reticular growth. Rhabdoid and sarcomatoid cytomorphology was seen in a subset. All tumors showed PAX8 nuclear positivity and SMARCB1 loss, with OCT3/4 expression in 4 of 5 cases. In summary, this first series of renal cell carcinoma, unclassified, with medullary phenotype documents tumors with morphologic, immunophenotypic, and prognostic features of RMC occurring in individuals without sickle cell trait. Although greater biologic and molecular understanding is needed, the available evidence points to these cases representing a sporadic counterpart to sickle cell trait-associated RMC.
肾髓质癌(RMC)是一种起源于集合系统的高度侵袭性肾细胞癌,需要与镰状细胞性状状态进行仔细关联。一组国际专家最近提出了临时诊断术语,即未分类的具有髓质表型的肾细胞癌,这是基于在一个经证实没有血红蛋白病的个体中遇到了一种具有RMC形态和免疫表型的极其罕见的肿瘤。在此,我们将这一观察结果扩展至5例此类肿瘤的队列,这些肿瘤在形态上与RMC相似,免疫组化显示缺乏SMARCB1表达,但每例均无血红蛋白病的证据。这些肿瘤发生在4名男性和1名女性中,平均年龄为44岁,分别位于3个左肾和2个右肾。临床上,侵袭性明显,所有5例均累及肾周脂肪组织,5例中有4例发生淋巴结转移,5例中有4例在3 - 27个月内死于疾病。组织学切片显示为低分化腺癌,通常具有实性和巢状生长模式,以及浸润性腺管、小管乳头状、筛状或网状生长。部分病例可见横纹肌样和肉瘤样细胞形态。所有肿瘤均显示PAX8核阳性和SMARCB1缺失,5例中有4例表达OCT3/4。总之,这第一组未分类的具有髓质表型的肾细胞癌病例记录了在没有镰状细胞性状的个体中发生的具有RMC形态、免疫表型和预后特征的肿瘤。尽管需要对生物学和分子机制有更深入的了解,但现有证据表明这些病例代表了与镰状细胞性状相关的RMC的散发性对应物。